liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Serum cholesterol and apolipoprotein B levels may reflect disease activity in ovarian cancer patients.
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för kliniska vetenskaper. Linköpings universitet, Hälsouniversitetet. Department of Gynecologic Oncology, Karolinska Hospital, Stockholm, Sweden.
Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för läkemedelsforskning. Linköpings universitet, Hälsouniversitetet.
1996 (Engelska)Ingår i: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 35, nr 8, s. 1007-10Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Data in the literature demonstrates increased receptor-mediated uptake of low density lipoprotein (LDL) in many types of malignant cells compared with normal cells. In acute leukemia, an inverse correlation has been demonstrated between disease activity and plasma cholesterol. To explore whether this is true also for ovarian cancer a case-control study was performed. We serially collected blood samples and assayed serum cholesterol and apolipoprotein B (the receptor recognizing moiety of LDL) in 10 patients with ovarian cancer. At diagnosis, the patients had lower mean cholesterol levels compared with 6 healthy women. An increase was found after primary surgery and after successful initial chemotherapy. The 5 patients who are in complete remission after a mean follow-up time of 79 months had higher cholesterol and apolipoprotein B levels at their last visit than at diagnosis. In contrast, a reduction of the two analytes was found in the patients who died from their ovarian cancer 15 to 28 months after diagnosis. The results may open a possibility for targetted chemotherapy in ovarian cancer with LDL as a drug carrier.

Ort, förlag, år, upplaga, sidor
1996. Vol. 35, nr 8, s. 1007-10
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-113902PubMedID: 9023386OAI: oai:DiVA.org:liu-113902DiVA, id: diva2:785649
Tillgänglig från: 2015-02-03 Skapad: 2015-02-03 Senast uppdaterad: 2017-12-05

Open Access i DiVA

Fulltext saknas i DiVA

PubMed

Personposter BETA

Avall-Lundqvist, E HPeterson, C O

Sök vidare i DiVA

Av författaren/redaktören
Avall-Lundqvist, E HPeterson, C O
Av organisationen
Avdelningen för kliniska vetenskaperHälsouniversitetetAvdelningen för läkemedelsforskning
I samma tidskrift
Acta Oncologica
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetricpoäng

pubmed
urn-nbn
Totalt: 143 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf